Formycon AG 2024 AR2
The report highlights Formycon's significant operational progress in 2024, including the regulatory approvals of biosimilar candidates FYB202 in the US and EU, and FYB203 in the US. The company successfully uplisted to the Prime Standard segment of the Frankfurt Stock Exchange and was subsequently included in the SDAX and TecDAX indexes. Formycon also initiated clinical development for its immuno-oncology candidate FYB206 and expanded its pipeline with the new immunology project FYB210. Financially, the company secured a strategic investment of ‒82.84 million from Gedeon Richter Plc. through a private placement capital increase.
Company: Formycon AG
Sector: Professional & technical services
Country: Germany
Year: 2024
Type: AR2
Pages: 215
Back to company
Formycon AG
Annual Report
The report highlights Formycon's significant operational progress in 2024, including the regulatory approvals of biosimilar candidates FYB202 in the US and EU, and FYB203 in the US. The company successfully uplisted to the Prime Standard segment of the Frankfurt Stock Exchange and was subsequently included in the SDAX and TecDAX indexes. Formycon also initiated clinical development for its immuno-oncology candidate FYB206 and expanded its pipeline with the new immunology project FYB210. Financially, the company secured a strategic investment of ‒82.84 million from Gedeon Richter Plc. through a private placement capital increase.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees